Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours
Male
Lung Neoplasms
Esophageal Neoplasms
Genital Neoplasms, Female
Medical Oncology
Prognosis
Disease-Free Survival
Tumor Burden
3. Good health
03 medical and health sciences
Treatment Outcome
0302 clinical medicine
Fluorodeoxyglucose F18
Head and Neck Neoplasms
Predictive Value of Tests
Neoplasms
Positron-Emission Tomography
Carcinoma, Squamous Cell
Humans
Female
Glycolysis
Neoplasm Staging
DOI:
10.1007/s00259-012-2280-z
Publication Date:
2012-11-13T16:30:21Z
AUTHORS (5)
ABSTRACT
Data available in patients suffering from squamous cell carcinoma of the head and neck, lung carcinoma, oesophageal carcinoma and gynaecological malignancies suggest that metabolic tumour volume and to a lesser extent total lesion glycolysis have the potential to become valuable in the imaging of human solid tumours as prognostic biomarkers for short- to intermediate-term survival outcomes, adding value to clinical staging, for assessment of response to treatment with neoadjuvant and concurrent chemotherapy, and for treatment optimization; for example, based on early treatment response assessment using changes in metabolic tumour volume over time, it might be possible to select patients who require a more aggressive treatment to improve their outcome. Prospective studies enrolling consecutive patients, adopting standardized protocols for FDG PET acquisition and processing, adjusting for potential confounders in the analysis (tumour size and origin) and determining the optimal methodology for determination of these novel markers are mandatory.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (82)
CITATIONS (138)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....